TP53 and B-cell chronic lymphocytic leukemia: In addition, a recent randomized trial comparing ibrutinib-rituximab to ibrutinib monotherapy for patients with relapsed or TP53 aberrant CLL found earlier peripheral lymphocyte count normalisation, CR and more frequent attainment of BM uMRD status with combination treatment; however, this did not translate to an improvement in PFS or OS over a median follow up of three years[105].